Open-Angle Glaucoma Market Size Is Expected to Grow at a Significant CAGR During the Forecast Period of 2025-2034 | DelveInsight

DelveInsight's "Open-angle Glaucoma Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of OAG, historical and forecasted epidemiology as well as the OAG market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Open-Angle Glaucoma Market Report @ https://www.delveinsight.com/report-store/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Open-Angle Glaucoma Market Report
• The Open-Angle Glaucoma Market is projected to grow at a significant CAGR by 2034 in leading countries (US, EU4, UK and Japan).
• The leading Open-Angle Glaucoma Companies include Ocuvex Therapeutics, Thea Pharma, Omikron Italia, PolyActiva Pty, and others.
• In the US, approximately 80% of all glaucoma cases are classified as OAG, making it the most prevalent form of glaucoma in the country.
• In the US, at least 2.7 million individuals aged 40 and older have been diagnosed with glaucoma.
• In Europe, 7.8 million people were affected by primary OAG, with a total prevalence of 2.51%.
• The most common type of glaucoma in the UK is primary OAG, affecting 2% of individuals older than 40 years and 10% of individuals older than 75 years.
• Male-to-female prevalence ratios ranged from 0.39 to 2.61, indicating that men are found to be more susceptible to primary OAG than women.
• Promising Open-Angle Glaucoma Therapies include Citicoline (Omikron Italia), AMDX-2011P (Amydis), PA5108 (PolyActiva Pty), PER-001 (Perfuse Therapeutics), AGN-193408 SR (AbbVie), among others.

Request for Unlocking the CAGR of the Open-Angle Glaucoma Market @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Recent Developments in the Open-Angle Glaucoma Market
• In June 2025, Qlaris Bio presented new data on its lead investigational compound, QLS-111, at the 2025 World Glaucoma Congress (WGC), including results from the Phase II 'Osprey' (QC-111-201) studies in patients with primary open-angle glaucoma (POAG) and ocular hypertension.

What is Open-Angle Glaucoma?
Open-angle glaucoma is a chronic, progressive eye disease characterized by the gradual blockage of the eye's drainage canals, leading to increased intraocular pressure and damage to the optic nerve. Primary open-angle glaucoma (POAG) is the most common type, characterized by increased resistance to drainage in the trabecular meshwork, while the drainage angle between the cornea and iris remains open. OAG is a chronic, progressive, and irreversible multifactorial optic neuropathy characterized by an open angle of the anterior chamber, typical optic nerve head changes, retinal nerve fiber layer thinning, and progressive loss of peripheral vision. Central visual field loss and blindness can occur in advanced stages. Although increased intraocular pressure is a significant risk factor, pressure levels greater than 21 mm Hg do not necessarily cause glaucoma and optic nerve damage in all patients, and some individuals with ocular hypertension maintain normal visual fields and healthy optic nerves.

Open-Angle Glaucoma Epidemiology Segmentation in the 7MM
• Total Open-Angle Glaucoma Prevalent Cases
• Open-Angle Glaucoma Gender-specific Cases
• Open-Angle Glaucoma Age-specific Cases
• Open-Angle Glaucoma Type-specific Cases

Download the report to understand which factors are driving Open-Angle Glaucoma epidemiology trends @ https://www.delveinsight.com/report-store/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Open-Angle Glaucoma Approved Therapies
• OMLONTI (omidenepag isopropyl ophthalmic solution): Ocuvex Therapeutics
OMLONTI is a relatively selective prostaglandin EP2 receptor agonist, which increases aqueous humor drainage through the conventional (trabecular) and uveoscleral outflow pathways, the only product with this pharmacological action. It was launched in Japan as EYBELIS ophthalmic solution 0.002% in November 2018, with regulatory filings across Asian countries in stages, and release in five countries and regions beginning February 2021. In September 2022, the US FDA approved OMLONTI 0.002% eye drops for reducing elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

• ZIOPTAN (tafluprost ophthalmic solution): Thea Pharma
ZIOPTAN, a prostaglandin analog, is a selective FP prostanoid receptor agonist believed to reduce intraocular pressure by increasing uveoscleral outflow. It is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In February 2012, the US FDA approved ZIOPTAN, a preservative-free prostaglandin analog, for this indication. Prasco Laboratories has also launched an Authorized Generic of ZIOPTAN, its first Authorized Generic launch, in partnership with Thea Pharma.
Open-Angle Glaucoma Pipeline Analysis

• Citicoline: Omikron Italia
Citicoline's mechanism of action is multifarious, including preservation of cardiolipin and sphingomyelin, restoration of phosphatidylcholine, stimulation of glutathione synthesis, lowering of glutamate concentration, and rescuing mitochondrial function, among others. It is currently in Phase II development for open-angle glaucoma patients.

• PA5108: PolyActiva Pty
The PA5108 Ocular Implant employs the proprietary Prezia Sustained Drug Delivery Technology to release a constant daily dose of latanoprost free acid, designed for zero-order drug release and rapid, complete, non-toxic biodegradation soon after treatment ends. It is currently in Phase II development for primary open-angle glaucoma. In December 2024, PolyActiva reported positive Phase II results, meeting key efficacy and safety endpoints with significant reductions in intraocular pressure over 26 weeks.

Open-Angle Glaucoma Companies
Ocuvex Therapeutics, Thea Pharma, Omikron Italia, PolyActiva Pty, and others

Discover more about therapies set to grab major Open-Angle Glaucoma market share @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Open-Angle Glaucoma Market Outlook
The Open-Angle Glaucoma treatment landscape has evolved significantly, yet remains centered on intraocular pressure reduction as the primary strategy to slow disease progression. Marketed therapies include FP receptor agonists such as ZIOPTAN and XALATAN, which enhance uveoscleral outflow, and beta-blockers like timolol, which reduce aqueous humor production. Alpha agonists (e.g., brimonidine) and carbonic anhydrase inhibitors (e.g., dorzolamide) provide additional intraocular pressure-lowering options. Newer agents such as OMLONTI, an EP2 receptor agonist, and RIPASUDIL, a Rho kinase inhibitor, offer novel mechanisms to enhance trabecular outflow with potential neuroprotective benefits. To address adherence issues, implantable therapies such as DURYSTA (bimatoprost intracameral implant) have been introduced, offering extended intraocular pressure control with a single administration. Minimally invasive glaucoma surgery (MIGS) devices like iStent, Hydrus Microstent, and Xen Gel Stent are increasingly used for patients needing surgical intervention, offering a safer profile than traditional filtering surgeries.

Emerging adjunctive options such as Citicoline, a neuroprotective compound, are under investigation for supporting retinal ganglion cell health and visual function, as treatment shifts toward individualized, long-term management strategies combining pressure-lowering, neuroprotection, and improved patient compliance.

Scope of the Open-Angle Glaucoma Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM (US, EU4, UK, and Japan)
• Open-Angle Glaucoma Companies: Ocuvex Therapeutics, Thea Pharma, Omikron Italia, PolyActiva Pty, and others
• Open-Angle Glaucoma Therapies: OMLONTI, ZIOPTAN, Citicoline, PA5108, and others
• Open-Angle Glaucoma Therapeutic Assessment: Open-Angle Glaucoma current marketed and emerging therapies
• Open-Angle Glaucoma Market Dynamics: Open-Angle Glaucoma market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Open-Angle Glaucoma Unmet Needs, KOL's views, Analyst's views, Open-Angle Glaucoma Market Access and Reimbursement

To know more about Open-Angle Glaucoma companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of OAG
4. Key Events
5. OAG Epidemiology and Market Forecast Methodology
6. OAG Market Overview at a Glance
7. Disease Background and Overview: OAG
8. Treatment and Management
9. Epidemiology and Patient Population of OAG in the 7MM
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. OAG: Seven Major Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.